Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

Citation metadata

From: Cancer(Vol. 116, Issue 16)
Publisher: J.B. Lippincott Company
Document Type: Clinical report

Document controls

Main content

Source Citation

Source Citation   

Gale Document Number: GALE|A235237331